Cargando…
Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report
RATIONALE: Factor X (FX) deficiency is a rare autosomal recessive bleeding disorder. The majority of patients carry a missense mutation in F10, and patients with bleeding disorders are either homozygous or compound heterozygous for F10. Nonsense mutations are exceptionally rare, and a heterozygous n...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999474/ https://www.ncbi.nlm.nih.gov/pubmed/29879041 http://dx.doi.org/10.1097/MD.0000000000010950 |
_version_ | 1783331432595193856 |
---|---|
author | Arita, Kotaro Niimi, Hideki Yamagishi, Nana Ueno, Tomohiro Kitajima, Isao Sugiyama, Toshiro |
author_facet | Arita, Kotaro Niimi, Hideki Yamagishi, Nana Ueno, Tomohiro Kitajima, Isao Sugiyama, Toshiro |
author_sort | Arita, Kotaro |
collection | PubMed |
description | RATIONALE: Factor X (FX) deficiency is a rare autosomal recessive bleeding disorder. The majority of patients carry a missense mutation in F10, and patients with bleeding disorders are either homozygous or compound heterozygous for F10. Nonsense mutations are exceptionally rare, and a heterozygous nonsense mutation is not considered to cause bleeding disorders. PATIENT CONCERNS: A 35-year-old Japanese female with an incidental hemorrhage after gynecologic polypectomy was referred to our hospital. DIAGNOSES: Following differential diagnostic workup, including cross-mixing test, congenital FX deficiency was strongly suspected. INTERVENTION: Coagulation tests and mutation analyses were conducted for the patient and her parents. OUTCOMES: Mutation analysis revealed that she carried a heterozygous nonsense mutation in F10. Pedigree analysis revealed that the mutation was inherited from her mother although there was no familial history of bleeding or hemostatic disturbance. LESSONS: Hemostatic disturbance may occur even in a patient with heterozygous F10. Because heterozygous nonsense mutation in F10 is expected to be hidden in an apparently healthy population, as observed in our patient, unexpected hemostatic disturbance may occur, particularly during the use of direct oral anticoagulant (DOAC)-targeting factor Xa for thrombotic diseases. FX activity should be evaluated before prescribing DOACs to patients. |
format | Online Article Text |
id | pubmed-5999474 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-59994742018-06-20 Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report Arita, Kotaro Niimi, Hideki Yamagishi, Nana Ueno, Tomohiro Kitajima, Isao Sugiyama, Toshiro Medicine (Baltimore) Research Article RATIONALE: Factor X (FX) deficiency is a rare autosomal recessive bleeding disorder. The majority of patients carry a missense mutation in F10, and patients with bleeding disorders are either homozygous or compound heterozygous for F10. Nonsense mutations are exceptionally rare, and a heterozygous nonsense mutation is not considered to cause bleeding disorders. PATIENT CONCERNS: A 35-year-old Japanese female with an incidental hemorrhage after gynecologic polypectomy was referred to our hospital. DIAGNOSES: Following differential diagnostic workup, including cross-mixing test, congenital FX deficiency was strongly suspected. INTERVENTION: Coagulation tests and mutation analyses were conducted for the patient and her parents. OUTCOMES: Mutation analysis revealed that she carried a heterozygous nonsense mutation in F10. Pedigree analysis revealed that the mutation was inherited from her mother although there was no familial history of bleeding or hemostatic disturbance. LESSONS: Hemostatic disturbance may occur even in a patient with heterozygous F10. Because heterozygous nonsense mutation in F10 is expected to be hidden in an apparently healthy population, as observed in our patient, unexpected hemostatic disturbance may occur, particularly during the use of direct oral anticoagulant (DOAC)-targeting factor Xa for thrombotic diseases. FX activity should be evaluated before prescribing DOACs to patients. Wolters Kluwer Health 2018-06-18 /pmc/articles/PMC5999474/ /pubmed/29879041 http://dx.doi.org/10.1097/MD.0000000000010950 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Research Article Arita, Kotaro Niimi, Hideki Yamagishi, Nana Ueno, Tomohiro Kitajima, Isao Sugiyama, Toshiro Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report |
title | Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report |
title_full | Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report |
title_fullStr | Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report |
title_full_unstemmed | Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report |
title_short | Factor X heterozygous mutation in a patient with potential risk of bleeding: A case report |
title_sort | factor x heterozygous mutation in a patient with potential risk of bleeding: a case report |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999474/ https://www.ncbi.nlm.nih.gov/pubmed/29879041 http://dx.doi.org/10.1097/MD.0000000000010950 |
work_keys_str_mv | AT aritakotaro factorxheterozygousmutationinapatientwithpotentialriskofbleedingacasereport AT niimihideki factorxheterozygousmutationinapatientwithpotentialriskofbleedingacasereport AT yamagishinana factorxheterozygousmutationinapatientwithpotentialriskofbleedingacasereport AT uenotomohiro factorxheterozygousmutationinapatientwithpotentialriskofbleedingacasereport AT kitajimaisao factorxheterozygousmutationinapatientwithpotentialriskofbleedingacasereport AT sugiyamatoshiro factorxheterozygousmutationinapatientwithpotentialriskofbleedingacasereport |